Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities

LOS ANGELES, CA -- (Marketwired) -- 04/12/17 -- Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the "Company") today,…

Continue Reading